Understanding the risk of recurrent atrial fibrillation after heart procedure
Prospective Cohort Study of the Risk of Recurrent Atrial Fibrillation After Radiofrequency Ablation
Peking University Third Hospital · NCT05638841
This study looks at patients with atrial fibrillation who have had a heart procedure to see what factors might cause their condition to come back.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University Third Hospital (other) |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05638841 on ClinicalTrials.gov |
What this trial studies
This observational study involves collecting clinical data from patients with atrial fibrillation who have undergone catheter ablation at Peking University Third Hospital. The aim is to identify risk factors associated with the recurrence of atrial fibrillation and to analyze major clinical events in these patients through outpatient follow-up. By continuously including patients in the study, researchers hope to enhance the management strategies for atrial fibrillation. The study focuses on understanding how different factors influence patient outcomes post-ablation.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with confirmed atrial fibrillation.
Not a fit: Patients with hematological diseases, autoimmune diseases, malignant tumors, or severe cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management and prevention strategies for patients at risk of recurrent atrial fibrillation.
How similar studies have performed: Other studies have explored similar risk factors in atrial fibrillation, indicating that this approach has potential for meaningful insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\) Age \> 18 * 2\) ECG or holter electrocardiogram confirmed atrial fibrillation Exclusion Criteria: * 1\) Hematological diseases, autoimmune diseases and malignant tumors * 2\) Immobility caused by hemiplegia or severe trauma * 3\) The expected survival time is less than 2 years * 4\) Poor compliance and high risk of expected loss of follow-up * 5\) Disorders of consciousness or Alzheimer's disease
Where this trial is running
Beijing
- Peking-University-Third-Hospital — Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Yanguang Li, Doctor
- Email: liyanguangsuper@163.com
- Phone: +8613693327068
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atrial Fibrillation